Physician profile
John M Buday
NPI 1326017047
$7,163.57
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,235 · 2020: $880 · 2021: $1,031 · 2022: $1,101 · 2023: $1,504 · 2024: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.51 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.57 | 2019-2024 | Qulipta, Ubrelvy, Botox |
| Biogen, INC. | $828.16 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Jazz Pharmaceuticals INC. | $504.13 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $482.13 | 2019-2024 | Austedo Xr, Austedo |
| Ucb, INC. | $473.10 | 2019-2024 | Briviact, Nayzilam |
| Alexion Pharmaceuticals, INC. | $356.63 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $343.04 | 2019-2024 | Amyvid, Reyvow, Emgality |
| Emd Serono, INC. | $301.65 | 2019-2024 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $267.08 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $205.54 | 2019-2021 | |
| Amgen INC. | $185.75 | 2019-2022 | |
| Kyowa Kirin, INC. | $182.79 | 2019-2023 | Nourianz |
| Genzyme Corporation | $181.86 | 2019-2022 | |
| Genentech USA, INC. | $179.70 | 2019-2024 | Enspryng, Ocrevus |
| Neurelis, INC. | $156.45 | 2020-2023 | Valtoco |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Buday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.